Cargando…
Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary
We report on children with cancer in Hungary suffering from COVID-19, surveying a 13-months-long period of time. We performed a retrospective clinical trial studying the medical documentation of children treated in seven centers of the Hungarian Pediatric Oncology-Hematology Group. About 10% of chil...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008132/ https://www.ncbi.nlm.nih.gov/pubmed/35431663 http://dx.doi.org/10.3389/pore.2022.1610261 |
_version_ | 1784686980662034432 |
---|---|
author | Müller, Judit Szűcs-Farkas, Dóra Szegedi, István Csóka, Monika Garami, Miklós Tiszlavicz, Lilla Györgyi Hauser, Péter Kriván, Gergely Csanádi, Krisztina Ottóffy, Gábor Nagy, Béla Kiss, Csongor Kovács, Gábor |
author_facet | Müller, Judit Szűcs-Farkas, Dóra Szegedi, István Csóka, Monika Garami, Miklós Tiszlavicz, Lilla Györgyi Hauser, Péter Kriván, Gergely Csanádi, Krisztina Ottóffy, Gábor Nagy, Béla Kiss, Csongor Kovács, Gábor |
author_sort | Müller, Judit |
collection | PubMed |
description | We report on children with cancer in Hungary suffering from COVID-19, surveying a 13-months-long period of time. We performed a retrospective clinical trial studying the medical documentation of children treated in seven centers of the Hungarian Pediatric Oncology-Hematology Group. About 10% of children admitted to tertiary hemato-oncological centers for anti-neoplastic treatment or diagnosis for de novo malignancies were positive for SARS-CoV-2 infection. Nearly two-thirds of the infected patients were asymptomatic or had only mild symptoms but showed seropositivity by 1–4.5 months after positive PCR. One third of the SARS-CoV-2-positive children were hospitalized due to symptomatic COVID-19. Five children required antiviral treatment with remdesivir. One child was referred to the intensive care unit, requiring intubation and mechanical ventilation. Delay in the scheduled anti-cancer treatment did not exceed 2 weeks in the majority (89%) of cases. There was only one patient requiring treatment deferral longer than a month. There was no COVID-19-related death in patients under 18 years of age, and nor was multisystem inflammatory syndrome diagnosed. In conclusion, SARS-CoV-2 infection did not represent an untoward risk factor among children with cancer in Hungary. |
format | Online Article Text |
id | pubmed-9008132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90081322022-04-15 Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary Müller, Judit Szűcs-Farkas, Dóra Szegedi, István Csóka, Monika Garami, Miklós Tiszlavicz, Lilla Györgyi Hauser, Péter Kriván, Gergely Csanádi, Krisztina Ottóffy, Gábor Nagy, Béla Kiss, Csongor Kovács, Gábor Pathol Oncol Res Pathology and Oncology Archive We report on children with cancer in Hungary suffering from COVID-19, surveying a 13-months-long period of time. We performed a retrospective clinical trial studying the medical documentation of children treated in seven centers of the Hungarian Pediatric Oncology-Hematology Group. About 10% of children admitted to tertiary hemato-oncological centers for anti-neoplastic treatment or diagnosis for de novo malignancies were positive for SARS-CoV-2 infection. Nearly two-thirds of the infected patients were asymptomatic or had only mild symptoms but showed seropositivity by 1–4.5 months after positive PCR. One third of the SARS-CoV-2-positive children were hospitalized due to symptomatic COVID-19. Five children required antiviral treatment with remdesivir. One child was referred to the intensive care unit, requiring intubation and mechanical ventilation. Delay in the scheduled anti-cancer treatment did not exceed 2 weeks in the majority (89%) of cases. There was only one patient requiring treatment deferral longer than a month. There was no COVID-19-related death in patients under 18 years of age, and nor was multisystem inflammatory syndrome diagnosed. In conclusion, SARS-CoV-2 infection did not represent an untoward risk factor among children with cancer in Hungary. Frontiers Media S.A. 2022-03-31 /pmc/articles/PMC9008132/ /pubmed/35431663 http://dx.doi.org/10.3389/pore.2022.1610261 Text en Copyright © 2022 Müller, Szűcs-Farkas, Szegedi, Csóka, Garami, Tiszlavicz, Hauser, Kriván, Csanádi, Ottóffy, Nagy, Kiss and Kovács. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pathology and Oncology Archive Müller, Judit Szűcs-Farkas, Dóra Szegedi, István Csóka, Monika Garami, Miklós Tiszlavicz, Lilla Györgyi Hauser, Péter Kriván, Gergely Csanádi, Krisztina Ottóffy, Gábor Nagy, Béla Kiss, Csongor Kovács, Gábor Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary |
title | Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary |
title_full | Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary |
title_fullStr | Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary |
title_full_unstemmed | Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary |
title_short | Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary |
title_sort | clinical course of covid-19 disease in children treated with neoplastic diseases in hungary |
topic | Pathology and Oncology Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008132/ https://www.ncbi.nlm.nih.gov/pubmed/35431663 http://dx.doi.org/10.3389/pore.2022.1610261 |
work_keys_str_mv | AT mullerjudit clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT szucsfarkasdora clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT szegediistvan clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT csokamonika clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT garamimiklos clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT tiszlaviczlillagyorgyi clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT hauserpeter clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT krivangergely clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT csanadikrisztina clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT ottoffygabor clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT nagybela clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT kisscsongor clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary AT kovacsgabor clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary |